That widely missed Larew's estimate for $27.1 million. Chromium, 10x's oldest system, brought in $7.6 million. Its spatial instruments generated $11.4 million. "10x's Chromium business was likely ...

It believes Chromium will sustain “greater volume declines and/or pricing pressure than current management expectations, and thus perpetuate 10x Genomics’ margin degradation.” The bank sees ...

TXG's new lower-cost Chromium offerings could drive volume growth ... a conservative but optimistic outlook. Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene ...

Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.